PP
IOVA icon

Paloma Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Paloma Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,737
Closed -$499K – 2187
2020
Q4 		$499K Sell
10,737
-48,334
-82% -$1.92M 0.01% 916
2020
Q3 		$1.94M Sell
59,071
-124,146
-68% -$3.81M 0.05% 400
2020
Q2 		$5.03M Buy
+183,217
New +$6.02M 0.09% 290
2017
Q3 		– Sell
-18,400
Closed -$135K – 2248
2017
Q2 		$135K Buy
+18,400
New +$117K ﹤0.01% 2052

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Paloma Partners's IOVA Position: Q1 2021 in Review

Paloma Partners sold out of Iovance Biotherapeutics (IOVA) in Q1 2021, closing a stake of 10,737 shares — an estimated $499K sold.

Paloma Partners first reported a position in IOVA in Q2 2017 and held it in 4 quarters. The position peaked at $5.03M in Q2 2020. 252 funds tracked by Wall St. Rank hold IOVA as of Q1 2021.

  • Paloma Partners reported no remaining Iovance Biotherapeutics position as of Q1 2021 after selling out during the quarter.
  • Paloma Partners sold 10,737 Iovance Biotherapeutics shares in Q1 2021, an estimated $499K.
  • Paloma Partners first reported a position in Iovance Biotherapeutics in Q2 2017 and held it in 4 quarters.
  • Paloma Partners's Iovance Biotherapeutics position peaked at $5.03M in Q2 2020.
  • 252 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2021.

Based on Paloma Partners's 13F filing for Q1 2021, filed 17 May 2021.